Prognostic Impact of 21-Gene Recurrence Score in Patients With Stage IV Breast Cancer: TBCRC 013

Journal of Clinical Oncology

Volumn 34, Issue 20, 2016, Pages 2359-2365

  King, Tari A ^a   Lyman, Jaclyn P ^a   Gonen, Mithat ^a   Voci, Amy ^a   De Brot, Marina ^a   Boafo, Camilla ^a   Sing, Amy Pratt ^b   Hwang, E Shelley ^d   Alvarado, Michael D ^c   Liu, Minetta C ^e   Boughey, Judy C ^f   McGuire, Kandace P ^g   Van Poznak, Catherine H ^h   Jacobs, Lisa K ⁱ   Meszoely, Ingrid M ^j   Krontiras, Helen ^k   Babiera, Gildy V ^l   Norton, Larry ^a   Morrow, Monica ^a   Hudis, Clifford A ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b Genomic Health   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^f MAYO CLINIC   (United States)

^g UNIVERSITY OF PITTSBURGH   (United States)

^h UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

ⁱ JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^k UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

^l UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; ERBB2 PROTEIN, HUMAN;

21 GENE RECURRENCE SCORE; ADULT; AGED; ARTICLE; BREAST BIOPSY; BREAST CANCER; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CLINICAL DECISION MAKING; COHORT ANALYSIS; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FOLLOW UP; HUMAN; HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 POSITIVE BREAST CANCER; HUMAN TISSUE; INTERMEDIATE RISK POPULATION; LOW RISK POPULATION; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PRIMARY TUMOR; PRIORITY JOURNAL; PROGNOSTIC ASSESSMENT; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; SCORING SYSTEM; BREAST NEOPLASMS; CHEMISTRY; CLINICAL TRIAL; ETIOLOGY; FEMALE; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; TUMOR RECURRENCE;

ADULT; AGED; BREAST NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN;

EID: 84977504130     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.63.1960     Document Type: Article

References (16)

1. Paik S, Shak S, Tang G, et al: Amultigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351:2817-2826, 2004
2. Paik S, Tang G, Shak S, et al: Gene expression and benefit of chemotherapy in women with nodenegative, estrogen receptor-positive breast cancer. J Clin Oncol 24:3726-3734, 2006
3. Albain KS, Barlow WE, Shak S, et al: Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with nodepositive, oestrogen-receptor-positive breast cancer on chemotherapy: A retrospective analysis of a randomised trial. Lancet Oncol 11:55-65, 2010
4. Harris L, Fritsche H, Mennel R, et al: American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 25:5287-5312, 2007
5. National Comprehensive Cancer Network (NCCN): NCCN Clinical Practice Guidelines in Oncology: Breast Cancer (ed 20). Fort Washington, PA, National Comprehensive Cancer Network, 2014
6. Cardoso F, Costa A, Norton L, et al: 1st International consensus guidelines for advanced breast cancer (ABC 1). Breast 21:242-252, 2012
7. Cardoso F, Costa A, Norton L, et al: ESOESMO 2nd international consensus guidelines for advanced breast cancer (ABC2). Breast 23:489-502, 2014
8. Andre F, Slimane K, Bachelot T, et al: Breast cancer with synchronous metastases: Trends in survival during a 14-year period. J Clin Oncol 22: 3302-3308, 2004
9. Cardoso F: Metastatic breast cancer patients: The forgotten heroes! Breast 18:271-272, 2009
10. Foukakis T, Fornander T, Lekberg T, et al: Age-specific trends of survival in metastatic breast cancer: 26 years longitudinal data from a populationbased cancer registry in Stockholm, Sweden. Breast Cancer Res Treat 130:553-560, 2011
11. Largillier R, Ferrero JM, Doyen J, et al: Prognostic factors in 1,038 womenwith metastatic breast cancer. Ann Oncol 19:2012-2019, 2008
12. Sundquist M, Eriksson Z, Tejler G, et al: Trends in survival in metastatic breast cancer. Eur J Cancer 8:191, 2010
13. Hébert-Croteau N, Brisson J, Latreille J, et al: Compliance with consensus recommendations for systemic therapy is associated with improved survival of women with node-negative breast cancer. J Clin Oncol 22:3685-3693, 2004
14. Turner CT, Ro J, Andre F, et al: PALOMA3: A double-blind, phase III trial of fulvestrant with or without palbociclib in pre- and post-menopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer that progressed on prior endocrine therapy. J Clin Oncol 33, 2015 (suppl; abstr LBA502)
15. Dowsett M, Cuzick J, Wale C, et al: Prediction of risk of distant recurrence using the 21-gene Recurrence Score in node-negative and nodepositive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: A Trans ATAC study. J Clin Oncol 28:1829-1834, 2010
16. Tang G, Cuzick J, Costantino JP, et al: Risk of recurrence and chemotherapy benefit for patients with node-negative, estrogen receptor-positive breast cancer: Recurrence Score alone and integrated with pathologic and clinical factors. J Clin Oncol 29:4365-4372, 2011